Kilitch Drugs Complete Financial Statements
In FY2026, Kilitch Drugs (KILITCH) reported revenue ₹90 Cr, net profit ₹15 Cr and EPS ₹4.24, with a net profit margin of 16.7% and ROE of 7.5%. Full financial statements from FY2015 to FY2026 (12 years) — income statement, balance sheet and cash flow in ₹ Crores. Download as Excel or CSV. Explore KILITCH fundamental worth to estimate fundamental worth using multiple valuation models.
Complete Financial Data Export
Profitability Ratios
Balance Sheet Ratios
KILITCH Revenue, Net Profit & EBITDA — Year-on-Year Growth
KILITCH YoY (Mar 2025 vs Mar 2026) — revenue +42.9%, net profit +50.0%, EBITDA +43.8%, expenses +44.7%. For live price, earnings ratios and company overview, see KILITCH share price.
KILITCH Income Statement — Revenue, EBITDA & Net Profit
Kilitch Drugs revenue ₹90 Cr, EBITDA ₹23 Cr, net profit ₹15 Cr, EPS ₹4.24 (2026) — net profit margin 16.7%. Review KILITCH PE ratio trends to evaluate earnings-based valuation against sector peers.
| Particulars | Mar 2026 | Sept 2025 | Mar 2025 | Jun 2025 | Dec 2025 | Sept 2024 | Mar 2024 | Jun 2024 | Dec 2024 | Sept 2023 | Mar 2023 | Jun 2023 | Dec 2023 | Sept 2022 | Mar 2022 | Jun 2022 | Dec 2022 | Sept 2021 | Mar 2021 | Jun 2021 | Dec 2021 | Sept 2020 | Mar 2020 | Jun 2020 | Dec 2020 | Sept 2019 | Mar 2019 | Jun 2019 | Dec 2019 | Sept 2018 | Jun 2018 | Dec 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 90 | 56 | 63 | 46 | 55 | 53 | 45 | 36 | 58 | 42 | 47 | 37 | 35 | 31 | 37 | 34 | 31 | 24 | 21 | 21 | 36 | 19 | 13 | 11 | 21 | 16 | 19 | 12 | 17 | 29 | 31 | 9 |
| Expenses | 68 | 44 | 47 | 40 | 48 | 41 | 38 | 32 | 47 | 33 | 39 | 30 | 30 | 27 | 32 | 30 | 26 | 20 | 20 | 19 | 34 | 15 | 14 | 11 | 17 | 14 | 16 | 11 | 14 | 22 | 25 | 12 |
| EBITDA | 23 | 12 | 16 | 6 | 8 | 11 | 8 | 4 | 11 | 9 | 7 | 7 | 5 | 4 | 5 | 4 | 5 | 4 | 2 | 2 | 2 | 3 | -1 | -1 | 3 | 2 | 2 | 1 | 2 | 6 | 6 | -3 |
| Operating Profit Margin % | 25.00% | 10.00% | 24.00% | 8.00% | 11.00% | 13.00% | 16.00% | 5.00% | 16.00% | 21.00% | 14.00% | 17.00% | 7.00% | 13.00% | 14.00% | 10.00% | 13.00% | 16.00% | 2.00% | 5.00% | 2.00% | 16.00% | -20.00% | -11.00% | 15.00% | 11.00% | 15.00% | -7.00% | 10.00% | 17.00% | 11.00% | -42.00% |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 1 | 1 | 1 |
| Interest | 1 | 1 | 2 | 2 | 1 | 0 | 1 | 2 | 1 | 2 | 1 | 2 | 2 | 2 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 20 | 9 | 14 | 4 | 6 | 10 | 5 | 2 | 8 | 7 | 5 | 5 | 3 | 2 | 4 | 3 | 3 | 3 | 1 | 1 | 2 | 3 | -2 | -2 | 3 | 2 | 1 | 0 | 2 | 6 | 5 | -4 |
| Tax | 5 | 1 | 4 | 1 | 1 | 2 | 2 | 2 | 3 | 2 | 2 | 2 | 1 | 0 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 0 | 1 | 0 | 1 | 2 | 1 | 1 |
| Net Profit | 15 | 8 | 10 | 2 | 4 | 9 | 4 | 0 | 6 | 5 | 3 | 3 | 2 | 2 | 2 | 2 | 2 | 3 | 1 | 1 | 1 | 2 | -1 | -1 | 2 | 1 | 1 | 0 | 1 | 4 | 4 | -5 |
| Earnings Per Share (₹) | 4.24 | 4.97 | 6.47 | 1.88 | 2.50 | 5.36 | 2.24 | 0.83 | 3.71 | 2.93 | 2.29 | 2.15 | 1.85 | 1.56 | 1.86 | 1.34 | 1.52 | 1.39 | 0.46 | 0.76 | 0.72 | 1.34 | -0.81 | -0.86 | 1.43 | 0.87 | 0.30 | -0.13 | 0.62 | 3.01 | 2.87 | -3.33 |
KILITCH Balance Sheet — Assets, Liabilities & Shareholders' Equity
KILITCH total assets ₹313 Cr, total equity ₹201 Cr, total liabilities ₹ Cr (2025) — ROE 7.5%.
| Particulars | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||||
| Total Assets | 313 | 240 | 220 | 210 | 203 | 143 | 144 | 128 | 113 | 117 | 127 |
| Current Assets | 174 | 146 | 126 | 114 | 80 | 56 | 65 | 63 | 49 | 47 | 47 |
| Fixed Assets | 64 | 62 | 64 | 65 | 30 | 32 | 32 | 33 | 33 | 42 | 9 |
| Capital Work in Progress | 47 | 6 | 4 | 3 | 66 | 30 | 20 | 3 | 1 | 0 | 0 |
| Investments | 72 | 72 | 62 | 71 | 60 | 52 | 53 | 56 | 53 | 23 | 25 |
| Other Assets | 129 | 100 | 90 | 71 | 47 | 30 | 38 | 35 | 26 | 51 | 93 |
| LIABILITIES | |||||||||||
| Total Liabilities | |||||||||||
| Current Liabilities | 28 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Non-Current Liabilities | |||||||||||
| SHAREHOLDERS' EQUITY | |||||||||||
| Total Equity | 201 | 176 | 151 | 140 | 130 | 121 | 123 | 113 | 101 | 109 | 120 |
| Share Capital | 16 | 16 | 16 | 16 | 16 | 15 | 15 | 14 | 13 | 13 | 13 |
| Reserves & Surplus | 186 | 160 | 131 | 121 | 112 | 103 | 106 | 96 | 88 | 96 | 107 |
KILITCH Cash Flow Statement — Operating, Investing & Financing
Kilitch Drugs operating cash flow ₹18 Cr, investing ₹-40 Cr, financing ₹13 Cr, net cash flow ₹-9 Cr (2025).
| Particulars | March 2025 | March 2024 | March 2023 | March 2022 | March 2021 | March 2020 | March 2019 | March 2018 | March 2017 | March 2016 | March 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | 18 | -2 | 3 | 6 | 46 | 5 | 0 | 1 | 1 | 17 | -8 |
| Investing Activities | -40 | -8 | 8 | -15 | -38 | -10 | -14 | -4 | -2 | -20 | -31 |
| Financing Activities | 13 | 9 | -1 | 7 | 2 | 1 | 17 | 6 | 0 | 0 | 0 |
| Net Cash Flow | -9 | -1 | 10 | -2 | 10 | -5 | 3 | 3 | 0 | -2 | -39 |